Astria Therapeutics
Astria Therapeutics was a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for allergic and immunological diseases, including navenibart for hereditary angioedema and STAR-0310 for atopic dermatitis. Acquired by BioCryst Pharmaceuticals in January 2026.
- Company typePrivate
- Founded2008
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Astria Therapeutics does
Astria Therapeutics was a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for patients with allergic and immunological diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company operated as a public entity on NASDAQ prior to its January 2026 acquisition. Its primary focus was hereditary angioedema (HAE), a rare and potentially life-threatening condition characterized by recurrent swelling attacks, with a secondary program targeting atopic dermatitis. The company employed 51–100 people and engaged stakeholders through medical conference presentations and investor relations activities rather than traditional commercial channels, consistent with its pre-commercial stage.
Astria's lead product candidate was navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein in Phase 3 development for HAE prophylaxis. The asset demonstrated strong efficacy, safety, and tolerability in the Phase 1b/2 ALPHA-STAR trial across 29 patients in six countries, with potential for every-three-month or every-six-month dosing intervals that would differentiate from existing therapies. The company's secondary program, STAR-0310, was an early-stage preclinical asset for moderate-to-severe atopic dermatitis, broadening the pipeline across the allergic and immunological disease spectrum.
Astria operated as a pre-revenue, clinical-stage entity, financing research and development through public equity markets. Between December 2022 and January 2024, the company raised approximately $289 million across three underwritten stock offerings, including a $125 million round in January 2024 led by RA Capital Management. BioCryst Pharmaceuticals completed its acquisition of Astria on January 23, 2026 for approximately $700 million, financed through a combination of cash on hand, a $396.6 million Blackstone financing facility, and 37.3 million BioCryst shares. Post-acquisition, Astria's CEO Jill C. Milne joined BioCryst's Board of Directors and other former Astria executives assumed leadership roles in the combined company.
Astria Therapeutics firmographics
Firmographics- Name
- Astria Therapeutics
- Legal name
- Astria Therapeutics, Inc.
- Website
- https://astriatx.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Astria Therapeutics was a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for allergic and immunological diseases, including navenibart for hereditary angioedema and STAR-0310 for atopic dermatitis. Acquired by BioCryst Pharmaceuticals in January 2026.
- Ownership category
- akta.pro rank
Astria Therapeutics industry classification
Industry- Product category
- Hereditary Angioedema Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF)
Keywords
Where Astria Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Astria Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels2 records
Astria Therapeutics product offering
Product offeringCore offering
Astria Therapeutics developed monoclonal antibody therapies for allergic and immunologic diseases. Its lead product candidate, navenibart (STAR-0215), is a plasma kallikrein inhibitor in late-stage (Phase 3) clinical development for the prevention of hereditary angioedema attacks, designed as a long-acting injectable with potential for quarterly or biannual dosing. A second pipeline program, STAR-0310, was in preclinical development for atopic dermatitis.
Product overview
Astria Therapeutics was a biopharmaceutical company developing therapies for allergic and immunological diseases. Its lead product candidate was navenibart (STAR-0215), a monoclonal antibody inhibitor in late-stage clinical development for hereditary angioedema (HAE). The company also had an early-stage program, STAR-0310, for atopic dermatitis. Astria Therapeutics was acquired by BioCryst Pharmaceuticals in January 2026 for approximately $700 million.
Differentiator
Problem solved
Functional benefit
Products and services
- Navenibart (STAR-0215)
Quantifiable outcome
- Phase 1b/2 ALPHA-STAR trial showed strong efficacy, safety, and tolerability in 29 hereditary angioedema patients across six countries
Companies that use Astria Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Astria Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Astria Therapeutics partnerships and signals
Strategic signalScale indicators3 records
Recent moves7 records
Expansion highlights5 records
Astria Therapeutics competitors and assessment
Company assessmentDirect peers
- BioCryst Pharmaceuticals: Acquirer of Astria and direct competitor in HAE prophylaxis with Orladeyo (berotralstat), an oral plasma kallikrein inhibitor. BioCryst's commercial infrastructure now houses navenibart post-acquisition, making it the most directly comparable peer on both science and go-to-market.
- Pharming Group: Markets Ruconest (conestat alfa), a recombinant C1 esterase inhibitor for acute HAE attacks. Direct HAE competitor with a complementary mechanism to plasma kallikrein inhibition.
- CSL Behring: Markets Haegarda, a plasma-derived C1 esterase inhibitor for HAE prophylaxis. Established HAE player and direct competitor for prophylactic market share.
- KalVista Therapeutics: Developing sebetralstat, an oral plasma kallikrein inhibitor for on-demand HAE treatment. Direct competitor targeting the same plasma kallikrein pathway via a different modality.
Broad incumbents
- Takeda Pharmaceutical: Markets Takhzyro (lanadelumab), a monoclonal antibody plasma kallikrein inhibitor and the current standard-of-care HAE prophylactic. Direct competitor to navenibart on mechanism of action and indication.
- Regeneron Pharmaceuticals: Co-markets Dupixent (dupilumab), the leading IL-4/IL-13 monoclonal antibody for moderate-to-severe atopic dermatitis. Direct competitor to Astria's STAR-0310 atopic dermatitis program in the same allergic disease indication.
- Sanofi: Co-markets Dupixent with Regeneron for atopic dermatitis and has a broader immunology portfolio. Comparable to Astria's strategic interest in allergic/immunologic disease therapeutics.
- Leo Pharma: Markets Adbry (tralokinumab), an IL-13 monoclonal antibody for atopic dermatitis. Competes in the same atopic dermatitis indication as Astria's STAR-0310 pipeline program.
Emerging players
- Ionis Pharmaceuticals: Developing donidalorsen, an antisense oligonucleotide targeting prekallikrein for HAE prophylaxis. Competes on the same plasma kallikrein pathway with a differentiated nucleic-acid modality.
- Intellia Therapeutics: Developing NTLA-2002, an in vivo CRISPR-based gene editing therapy for HAE that targets the KLKB1 gene (kallikrein). Emerging modality competitor with potential one-time curative profile.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Astria Therapeutics social profiles
Digital presenceAstria Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Astria Therapeutics leadership team
Management profileNumber of profiles
Astria Therapeutics funding detail
Funding detailFunding overview
Funding rounds17 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Astria Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Astria Therapeutics
What does Astria Therapeutics do?
Astria Therapeutics developed monoclonal antibody therapies for allergic and immunologic diseases. Its lead product candidate, navenibart (STAR-0215), is a plasma kallikrein inhibitor in late-stage (Phase 3) clinical development for the prevention of hereditary angioedema attacks, designed as a long-acting injectable with potential for quarterly or biannual dosing. A second pipeline program, STAR-0310, was in preclinical development for atopic dermatitis.
Is Astria Therapeutics a public or private company?
Astria Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Astria Therapeutics founded?
Astria Therapeutics was founded in 2008. It employs 51 to 100 people.
Where is Astria Therapeutics based?
Astria Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are Astria Therapeutics's main competitors?
Direct peers on record are BioCryst Pharmaceuticals, Pharming Group, CSL Behring and KalVista Therapeutics. Broad incumbents are Takeda Pharmaceutical, Regeneron Pharmaceuticals, Sanofi and Leo Pharma. Emerging players are Ionis Pharmaceuticals and Intellia Therapeutics.
Does Astria Therapeutics have an API?
No public API is recorded for Astria Therapeutics.
What industry is Astria Therapeutics in?
Astria Therapeutics's product category is Hereditary Angioedema Biologics. Its primary akta.pro industry code is HLAIAHAF, Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor). Its NAICS code is 325414 and its SIC code is 2836.